| The biochemistry of P-glycoprotein-mediated multidrug resistance JA Endicott, V Ling Annual review of biochemistry 58 (1), 137-171, 1989 | 2779 | 1989 |
| Protein kinase inhibitors: insights into drug design from structure MEM Noble, JA Endicott, LN Johnson Science 303 (5665), 1800-1805, 2004 | 1680 | 2004 |
| Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases R Hoessel, S Leclerc, JA Endicott, MEM Nobel, A Lawrie, P Tunnah, ... Nature cell biology 1 (1), 60-67, 1999 | 1035 | 1999 |
| Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance JH Gerlach, JA Endicott, PF Juranka, G Henderson, F Sarangi, ... Nature 324 (6096), 485-489, 1986 | 858 | 1986 |
| The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases NR Brown, MEM Noble, JA Endicott, LN Johnson Nature cell biology 1 (7), 438-443, 1999 | 695 | 1999 |
| The structural basis for control of eukaryotic protein kinases JA Endicott, MEM Noble, LN Johnson Annual review of biochemistry 81 (1), 587-613, 2012 | 496 | 2012 |
| Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2 AM Lawrie, ME Noble, P Tunnah, NR Brown, LN Johnson, JA Endicott Nature structural biology 4 (10), 796-801, 1997 | 334 | 1997 |
| Molecular basis for the recognition of phosphorylated and phosphoacetylated histone h3 by 14-3-3 N Macdonald, JPI Welburn, MEM Noble, A Nguyen, MB Yaffe, D Clynes, ... Molecular cell 20 (2), 199-211, 2005 | 291 | 2005 |
| Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor TG Davies, J Bentley, CE Arris, FT Boyle, NJ Curtin, JA Endicott, ... Nature structural biology 9 (10), 745-749, 2002 | 282 | 2002 |
| Effects of phosphorylation of threonine 160 on cyclin-dependent kinase 2 structure and activity NR Brown, MEM Noble, AM Lawrie, MC Morris, P Tunnah, G Divita, ... Journal of Biological Chemistry 274 (13), 8746-8756, 1999 | 274 | 1999 |
| Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles CE Arris, FT Boyle, AH Calvert, NJ Curtin, JA Endicott, EF Garman, ... Journal of medicinal chemistry 43 (15), 2797-2804, 2000 | 271 | 2000 |
| The crystal structure of cyclin A NR Brown, MEM Noble, JA Endicott, EF Garman, S Wakatsuki, E Mitchell, ... Structure 3 (11), 1235-1247, 1995 | 256 | 1995 |
| Structural insights into the functional diversity of the CDK–cyclin family DJ Wood, JA Endicott Open biology 8 (9), 180112, 2018 | 223 | 2018 |
| CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases K Bettayeb, N Oumata, A Echalier, Y Ferandin, JA Endicott, H Galons, ... Oncogene 27 (44), 5797-5807, 2008 | 207 | 2008 |
| Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP M Lu, H Breyssens, V Salter, S Zhong, Y Hu, C Baer, I Ratnayaka, ... Cancer cell 23 (5), 618-633, 2013 | 196 | 2013 |
| Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects Y Mettey, M Gompel, V Thomas, M Garnier, M Leost, I Ceballos-Picot, ... Journal of medicinal chemistry 46 (2), 222-236, 2003 | 195 | 2003 |
| CDK1 structures reveal conserved and unique features of the essential cell cycle CDK NR Brown, S Korolchuk, MP Martin, WA Stanley, R Moukhametzianov, ... Nature communications 6 (1), 1-12, 2015 | 192 | 2015 |
| Inhibitor binding to active and inactive CDK2: the crystal structure of CDK2-cyclin A/indirubin-5-sulphonate TG Davies, P Tunnah, L Meijer, D Marko, G Eisenbrand, JA Endicott, ... Structure 9 (5), 389-397, 2001 | 188 | 2001 |
| The cyclin box fold: protein recognition in cell-cycle and transcription control MEM Noble, JA Endicott, NR Brown, LN Johnson Trends in biochemical sciences 22 (12), 482-487, 1997 | 187 | 1997 |
| Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex A Echalier, K Bettayeb, Y Ferandin, O Lozach, M Clément, A Valette, ... Journal of medicinal chemistry 51 (4), 737-751, 2008 | 176 | 2008 |
